Last reviewed · How we verify
Probiotic Clostridium Butyricum
At a glance
| Generic name | Probiotic Clostridium Butyricum |
|---|---|
| Also known as | Clostridium Butyricum Tablets |
| Sponsor | Shandong University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
- CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (PHASE1)
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (PHASE3)
- The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function (NA)
- Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss (PHASE2)
- A Probiotic Based Intervention in Pregnancies Complicated by GDM (PHASE2)
- The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotic Clostridium Butyricum CI brief — competitive landscape report
- Probiotic Clostridium Butyricum updates RSS · CI watch RSS
- Shandong University portfolio CI